TY -的T1 -协会Informant-Reported与认知和大脑记忆衰退恶化通过阿尔茨海默病神经病学临床连续摩根富林明——乔-神经病学SP - e2454 LP - - 10.1212 / WNL e2465做。半岛投注体育官网0000000000207338六世- 100是伊丽莎白库恩- 24盟盟-奥黛丽Perrotin盟Renaud拉抱着非盟-雪绒花Touron AU -苏菲Dautricourt盟马修Vanhoutte AU -丹尼斯薇薇安盟文森特de La Sayette AU -盖尔Chetelat盟的阿尔茨海默病的神经影像学Y1 - 2023/06/13 UR - //www.ebmtp.com/content/100/24/e2454.abstract N2 -背景和目标研究稀疏关于之间的关联informant-reported主观记忆衰退(线人报告)和阿尔茨海默病(AD)生物标记。半岛投注体育官网因此本研究旨在确定的临床相关性线人报告整个广告临床连续体,通过评估其特定的与淀粉样蛋白沉积的关系,认知和神经退化。方法从Imagerie参与者Multimodale de la病d 'Alzheimer联合国施塔德Precoce (IMAP +)初级群体和阿尔茨海默病神经影像倡议(ADNI)复制队列中;进行了多通道神经影像学和神经心理评估。后续数据IMAP +参与者/ 36个月也用于纵向分析。线人报告测量的认知困难量表(IMAP +)和日常认知(ADNI)。一般线性模型被用来评估之间的横向联系线人报告和淀粉pet,认知表现,和神经退行性变的老年痴呆症的签名(萎缩和代谢减退);而纵向联系在IMAP +线性mixed-effects模型评估。结果总共包括110 IMAP +参与者,包括32个认知未受损伤的老年人(控制、年龄:70.91±6.57岁,女:50%),25名患者主观认知能力下降(SCD, 65.88±6.64, 40%)、35岁患有轻度认知障碍(MCI, 72.49±7.5, 34%)和18 Alzheimer-type痴呆(AD痴呆,68.17±8.59,28%)。七百三十一包括ADNI参与者,包括157名对照(74.21±5.95,55%),84年SCD(72.00±5.41, 63%), 369年与MCI(71.84±7.4, 44%),和121 AD痴呆(74.29±7.75,40%)。 In IMAP+, a higher informant report strongly correlated to greater amyloid-PET, specifically in patients with MCI (β = 0.48, p = 0.003), and to lower cognitive performance in patients with SCD (global cognition, β = −0.41, p = 0.04) and MCI (memory, β = −0.37, p = 0.03). Findings in patients with MCI were replicated in the ADNI (amyloid-PET, β = 0.25, p < 0.001; memory, β = −0.22, p < 0.001) and extended to neurodegeneration in AD signature areas (β = −0.2, p < 0.001). Longitudinal analyses in IMAP+ showed links with global cognitive decline over time in patients with MCI (estimate −0.74, SE 0.26, p = 0.005) and SCD (estimate −0.36, SE 0.26, p = 0.02) where a higher baseline informant report also predicted an increased amyloid-PET over time (estimate 0.008, SE 0.003, p = 0.02).Discussion Altogether, our findings suggest that the informant report is particularly relevant in patients with MCI where it strongly relates to higher amyloid-PET, indicative of impairment due to AD.Trial Registration Information ClinicalTrials.gov Identifier: NCT01638949.AD dementia=Alzheimer-type dementia; ADNI=Alzheimer Disease Neuroimaging Initiative; CDS=Cognitive Difficulties Scale; CU=cognitively unimpaired; ESR=Encoding, Storage, and Retrieval; FDG=18F-fluorodeoxyglucose; FDR=false discovery rate; FLAIR=fluid-attenuated inversion recovery; GM=gray matter; IMAP+=Imagerie Multimodale de la maladie d'Alzheimer à un stade Précoce; I-SMD=Informant-reported Subjective Memory Decline; MCI=mild cognitive impairment; MMSE=Mini-Mental State Examination; SCD=subjective cognitive decline; Self-SMD=self-reported Subjective Memory Decline; SUVr=global neocortical standardized uptake value ratio ER -